The emerging matrix of immunosuppressive agents

Area of Science:

• Immunology
• Transplantation Medicine
• Pharmacology

Background:

• Current immunosuppressive drugs have advanced transplantation but cause significant toxicities due to widespread molecular targets.
• Targets like calcineurin, mTOR, and inosine monophosphate dehydrogenase affect multiple tissues, leading to collateral damage.
• There is a critical need for novel immunosuppressive strategies to mitigate these adverse effects.

Purpose of the Study:

• To outline the necessity for a fifth generation of immunosuppressive agents.
• To define the criteria for developing new immunosuppressants that minimize collateral toxicities.
• To emphasize the requirement for targeted therapies specific to the adaptive immune response.

Main Methods:

• Review of current immunosuppressive drug mechanisms and their associated toxicities.
• Analysis of molecular targets critical for adaptive immunity.
• Conceptual framework for the development of next-generation immunosuppressants.

Main Results:

• Identification of limitations in current immunosuppressive therapies, primarily stemming from off-target effects.
• Highlighting the potential of targeting molecules specific to the adaptive immune system.
• Establishing the rationale for a new class of immunosuppressants.

Conclusions:

• A fifth generation of immunosuppressants is required to improve patient safety and transplant success.
• Selective targeting of adaptive immune response molecules offers a promising strategy to avoid current toxicities.
• Future research should focus on identifying and validating novel targets for next-generation immunosuppression.